- Medication adherence could be blockbuster for specialty
- Adherence among chronic disease patients can lead to big savings
- Adults thirsty for weight-loss/nutrition drinks
- Pfizer forms licensing agreement with Seattle Genetics
- Novo Nordisk's Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin
ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.
Abbott announced Monday the approval of a 45-mg, six-month formulation of Lupron Depot (leuprolide acetate) for advanced prostate cancer. Previous formulations have allowed patients to receive the drug every month or every three or four months.
“Lupron Depot is an important treatment option for many patients with advanced prostate cancer,” Abbott VP global pharmaceutical development Eugene Sun said. “Approval of a new six-month formulation means that physicians and patients who have chosen Lupron Depot now have an additional treatment option.”